FDA Proposes New Regulatory Framework for Regenerative Medicine

Drug Industry Daily
The FDA unveiled its new regenerative medicine oversight framework — the regulation of promising stem cell treatments, engineered tissues and cell therapies — by publishing four guidance documents focused on speeding development and clarifying the agency’s enforcement actions over the next three years.

To View This Article:


Subscribe To Drug Industry Daily